|
 
- 积分
- 3053
- 威望
- 3053
- 包包
- 5595
|
Glance at last issue:0 a, g: d% H8 p7 e3 e
" n( R/ a* E1 `7 X1 K4 |+ z; F“During that surgery we would actually inject stem cells that have been differentiated to become a part of the nervous system into the spinal cord.”--Dr. Stephen McKenna, chief of Santa Clara Valley Medical Center’s rehabilitation trauma center.
5 e0 f: j2 v( r1 N o' |# E
( Y- H5 p. J4 u/ }- @- q; I5 M/ U0 O9 b"Until recently, we have not had any hope of restoring neurological function in people with spinal cord injury or stroke, or those with brain tumors or Alzheimer's disease. But now we're moving stem cell therapy into the clinic, which I feel is a tremendously important step. People are not mice or rats, and we can learn so much from clinical trials that we can never learn by studying animals."--Neuroscientist Gary Steinberg who led the Stanford team.& |; W% S6 ^) ~
9 A8 c: p) Y" ?% k8 G2 j
“The science has moved so fast that there hasn’t been much opportunity for the field to develop or reflect on norms or standards for sharing data and materials, or to# @2 c! r t1 l
engage in the sorts of collective action now needed in the field to allow both basic and translational science to move forward, and for society to see benefits in the form of new therapies and treatments.”--Debra Mathews, Ph.D., assistant director for science programs at the Johns Hopkins Berman Institute of Bioethics and a member of the Hinxton Group’s steering committee.
6 P2 I$ B% S; x4 F4 b. ~4 @8 R
$ n' w) y" I: a( A8 |& _2 H: f"When I came to ACT to try to do it with stem cells I couldn't because the rights to use embryonic stem cells for diabetes had been exclusively licensed to Geron. Here I was, a scientist trying to cure diabetes and I couldn't use my entire lifetime of expertise to try and develop that technology."--Bob Lanza, chief scientific officer at Advanced Cell Technology.- _" u% ?: |# S$ t% K. o
$ f: l* y4 m% F7 ~: @9 G9 }; q2 a" d"We are at a point in stem cell science where it is important that the community start to think about how intellectual property is being taken, how it is being protected and how data and material sharing are all impacting the science and the translation of science into treatments and valuable products."--Debra Mathews of Johns Hopkins University., j' Z4 L0 S/ D1 j/ V
7 K; \) m2 u1 J"What is significant about this work is that we've been able to very rapidly develop a chemically defined culture medium to replace serum and feeders for cultivating clinical-grade hES cells, thereby removing a major roadblock in the area of regenerative medicine."-- Chih-Ming Ho, the Ben Rich-Lockheed Martin Professor at the UCLA Henry Samueli School of Engineering and Applied Science and a member of the National Academy of Engineering.3 ]2 c' C' a% `% }2 e
3 X) W0 g, n, H6 i$ \* E* b1 m"My belief is that you need that mixed population of cells in order for this therapy to be effective. Everybody who is now seeing success with the use of these cells—almost all of them—are using a mixed population."--Stuart Williams, director of the Cardiovascular Innovation Institute in Louisville, Kentucky.
. \5 r1 X3 z8 Y* {0 H0 m3 \8 b
+ L/ \: O( n: N" P4 R' j* P“Like Christopher Reed, they have all their mind there. When you run a trial like that, it’s actually an important consideration. You need motivated patients to stick with you. A trial is not simply injecting stem cells. It’s everything that comes after that.”--Marco Lee, professor of neurosurgery of Stanford Hospital and Santa Clara Valley Medical Center. O, e( e7 R) S: |0 O" ~
$ e: D9 H& _ r( I"We are now close to the day when we will be able to hail a breakthrough in this important technology...China needs five to 10 years to shift from basic research to clinical application and another 10 years to realize large-scale clinical application. If there are any science projects that could win China a Nobel Prize during the next 10 years, the most likely candidate is its stem cell research."--Zhou Qi, chief scientist with the stem cell research project at the Chinese Academy of Sciences (CAS)
/ K8 @: n8 J* d4 _3 K
4 G- m1 I9 k) ~( \. Y$ ]$ P) T3 C"Currently, in efforts to devise therapies for motor neuron disease or spinal cord injury there is a lot of focus is on how to make neurons survive. That is important, but we also need to know how to properly form a synapse. If we cannot, the neuromuscular junction won't function correctly."--Kuo-Fen Lee, a professor in the Clayton Foundation Laboratories for Peptide Biology of Salk Institute.
8 w6 p/ l) ^' h& o4 R
. T: |/ e9 u6 [7 x+ v, b5 `. g"In 11 days, we went from skin cells to beating heart cells in a dish. It was phenomenal to see.It is like launching a rocket. Until now, people thought you needed to first land the rocket on the moon and then from there you could go to other planets. But here we show that just after the launch you can redirect the rocket to another planet without having to first go to the moon. This is a totally new paradigm."--Scripps Research Associate Professor Sheng Ding, Ph.D.
( K: T' a9 W4 b! J" A& R: W! o& g9 D" o& E$ O1 c: `# O z5 H5 z$ n
"We knew that Lin28 affects the expression of some important microRNAs. But we were surprised to find that it is doing something we didn't expect it to do. What Lin28 is doing is making all these stem cells work better. It's improving cell metabolism, helping those cells that are weaker survive."--Gordon Carmichael, UConn professor of genetics and developmental biology.) W7 Y' f) t; a* _) x7 }
+ K! O; i2 C8 Q1 Z
“Toronto is truly the city where stem cell science was born, thanks to Till and McCulloch.”--Dr. Christopher Paige, vice-president (research) at University Health Network." F; O! p2 O+ B. v! }5 @" J6 H
- [' e- G$ r# K( O- A
“These iPS cells are much safer than ones made with previous technologies because they don’t involve integrating foreign viruses that can potentially lead to uncontrolled, cancerous cell growth. This is important if iPS cells are to be used as therapies one day.”--Linzhao Cheng, Ph.D., an associate professor of medicine in the Division of Hematology and a member of the Johns Hopkins Institute of Cell Engineering.
8 J! w- @) S8 U8 t' M$ H. U
0 e% i6 a G1 [- ]"We identified several molecular barriers early in the reprogramming process and figured out how to remove them using miRNA. This is significant because it will enhance our ability to use iPS cells to model diseases in the laboratory and search for new therapies."--Tariq Rana, Ph.D., director of the RNA Biology program at Sanford-Burnham. ! K! a1 ~0 e! ^* Y4 S* m: U! A
$ x7 k0 i9 P: } k' w"If you look with blinders on, they look fairly similar. But if you zoom in you find different signatures of what an iPS cell is."--Joseph Ecker, a molecular geneticist at the Salk Institute.& L2 J0 y8 M" o8 k
* z0 W0 O* W: z"When we culture cells outside a normal organism they can acquire features that may not be compatible with life once they go back into an organism."--Richard Young, a stem-cell biologist at the Whitehead Institute in Cambridge, Massachusetts.
& X2 B. n- Y- u
) \: x+ T. J O"This study adds a new dimension to what we know about p63's role in stem cell function and the contribution of its various isoforms in cancer. It also adds new insight to the role of stem cells in cancer by showing that when more mature progenitors or committed cells accumulate genetic lesions that make them more stem-like, they tend to promote cancer."--Associate Professor Alea A. Mills at Cold Spring Harbor Laboratory (CSHL).
7 \; [' D3 t0 E; r8 P: G
% p5 M0 d0 r1 |; g7 d- x0 ~- I, V4 A"Given that age is the most consistent risk factor for Parkinson's, and we have an aging population, it is of utmost importance that we unravel the cellular, molecular, and genetic causes of the highly specific cell death characteristic of the disease and find new therapies to limit the social, economic and emotional impact."--Fred H. Gage, Ph.D., a professor in the Salk's Laboratory of Genetics and holder of the Vi and John Adler Chair for Research on Age-Related Neurodegenerative Diseases.
8 W# }7 u% T$ g4 N6 O: m R' w5 ~
* r9 t4 C4 v. q, a2 B! v& ]“But, we also see a fair amount of variation in the same regions of ES cell lines. Rather than saying iPS are different than ES cells, we conclude that they are both variable, typically in the same areas of the genome. If one investigated just one or two ES cell lines and compared these with a handful of iPS lines, one would inevitably find true significant differences. But if you look at the larger picture, you see a lot of ES cell lines have the same degree of variation in the same regions.”--Alexander Meissner, assistant professor at Harvard University and senior associate member at the Broad.- a% l9 p- L: A/ E. L
: T( ~- {8 |+ n6 e6 _
"This work could allow programmable cell therapies where the cell or the agent is the therapeutic. For example, depots containing specific agents could enhance cell survival or expression of a particular growth factor. Cells could also be used as a delivery vehicle to shuttle drugs to target tissues that may be useful to accelerate tissue regeneration, or to deliver chemotherapeutics to tumors while minimizing systemic side effects...We can exhibit exquisite control over cells in a [laboratory] dish—we can get them to do whatever we want. But when we transplant them into the body, their fate and function are at the mercy of the biological milieu. We typically lose complete control and this prevents us from achieving the promise of cell therapy."--Jeffrey Karp, leader of the work and co-director of the Center for Regenerative Therapeutics (ReGen Rx) at BWH.* p& a! ]" o0 \4 b, [/ I3 w2 C6 C
y6 X( T3 @0 @- t i* L( k“With animal sera or mouse feeder cells, the quality varies over different batches, so even if you buy the same product, one bottle of serum is different from the other one. So, your cell culture won’t be consistent. Our system successfully removed those feeder cells as well as the serum component of the media so we can have a better understanding, chemically, of what’s going on in the cells.”--Hideaki Tsutsui, UCLA investigator.
5 A _! G$ m0 ~# A, [; ?
! t# ~* V: r' w' L7 M"The results demonstrate a significant effect of nasal stem cell transplantations for sensorineural hearing loss. These cells can be obtained easily from the nasal cavity making this transplantation a potential treatment for other human conditions including Parkinson's disease and cardiac infarction."--Dr. Sharon Oleskevich from the Hearing Research Group at University of New South Wales.; B% X/ l2 j$ m k6 `
7 N0 V8 e2 y8 A5 t
“The lack of transparency about who owns what intellectual property rights can hamper stem cell research and development, and so can the resulting ambiguity of the distinction between what is private property and what is in the public domain.”--Debra Mathews, Ph.D., M.A., of the Johns Hopkins Berman Institute of Bioethics.
- }' E1 | Q% r
4 J8 t3 L! S/ z6 x7 k0 p C
6 Z1 l" f3 J: q4 L8 VThis issue:
! {3 h% L. k0 o( _) c \' R6 A6 ?. `! z8 W- ~4 z4 b% b# J" c! U
' d& N$ C; v+ ?' d, g
2 @; m7 P8 t( r6 I8 I0 rVideo news:6 p! A& M& ]4 p
Stem cell research to keep pets living longer: i- m2 X5 E- [$ g4 D! U: B
http://abclocal.go.com/kabc/stor ... alth&id=7961193
2 z+ P6 b& U2 U+ m7 x
" ]7 F6 E2 o( o8 `Stem Cell Progress Shared At La Jolla Meeting
$ U3 J9 I# j8 Q8 Ghttp://www.10news.com/video/26921874/index.html
; M1 ?6 A; Q! z9 M |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 20
包包 + 30
查看全部评分
|
发表于 2011-2-21 21:41
